# US 2024/0199720 A1 · Composition and method for preventing or treating sars-cov-2 infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0199720 A1 - Document ID: US20240199720A1 - Status: Published application - Kind: A1 - Application number: 18/540,384 - Filed: 2023-12-14 - Published: 2024-06-20 - Earliest claimed: 2022-12-14 - Assignees: National Yang Ming Chiao Tung University - Applicants: National Yang Ming Chiao Tung University - Inventors: Chia-Ching CHANG; Chia-Yu CHANG; Shin-Ru SHIH; Sheng-Yu HUANG - Web page: https://patentgrep.com/patent/US20240199720A1 ## CPC - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Provided is a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I). Also provided are a method for inhibiting combination between SARS-COV-2 and a cell of a subject and a method for preventing or treating SARS-COV-2 infection in a subject in need thereof, including contacting the cell or administering to the subject with the non-natural polypeptide. ## Claims ### Claim 1 A method for inhibiting combination between SARS-COV-2 and a cell of a subject in need thereof, comprising contacting the cell with an effective amount of a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I). ### Claim 2 (depends on 1) The method of claim 1, wherein the non-natural polypeptide has at least 75% sequence identity to MHC I. ### Claim 3 (depends on 1) The method of claim 1, wherein the non-natural polypeptide has an amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 5, or 6. ### Claim 4 (depends on 1) The method of claim 1, wherein the non-natural polypeptide shows binding activity to a spike protein receptor binding domain of the SARS-COV-2. ### Claim 5 (depends on 1) The method of claim 1, wherein the non-natural polypeptide consists of 10 to 400 amino acids. ### Claim 6 (depends on 1) The method of claim 1, wherein the non-natural polypeptide inhibits the combination between the SARS-COV-2 and a cell membrane receptor of the cell. ### Claim 7 (depends on 6) The method of claim 6, wherein the cell membrane receptor of the cell is angiotensin-converting enzyme II (ACE2). ### Claim 8 (depends on 1) The method of claim 1, wherein the SARS-COV-2 is a wild-type or a variant thereof. ### Claim 9 (depends on 8) The method of claim 8, wherein the variant is any one selected from the group consisting of Alpha, Beta, Gamma, Delta, and Omicron. ### Claim 10 A method for preventing or treating SARS-COV-2 infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises an effective amount of a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I) and a pharmaceutically acceptable carrier thereof. ### Claim 11 (depends on 10) The method of claim 10, wherein the non-natural polypeptide has at least 75% sequence identity to MHC I. ### Claim 12 (depends on 10) The method of claim 10, wherein the non-natural polypeptide has an amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 5, or 6. ### Claim 13 (depends on 10) The method of claim 10, wherein the non-natural polypeptide shows binding activity to a spike protein receptor binding domain of the SARS-COV-2. ### Claim 14 (depends on 10) The method of claim 10, wherein the non-natural polypeptide consists of 10 to 400 amino acids. ### Claim 15 (depends on 10) The method of claim 10, wherein the non-natural polypeptide inhibits combination between the SARS-COV-2 and a cell membrane receptor of a cell in the subject. ### Claim 16 (depends on 15) The method of claim 15, wherein the cell membrane receptor is angiotensin-converting enzyme II (ACE2). ### Claim 17 (depends on 10) The method of claim 10, wherein the SARS-COV-2 is a wild-type or a variant thereof. ### Claim 18 (depends on 17) The method of claim 17, wherein the variant is any one selected from the group consisting of Alpha, Beta, Gamma, Delta, and Omicron. ### Claim 19 A non-natural polypeptide having at least 70% sequence identity to at least one of SEQ ID NOs: 1, 2, 3, 4, 5, or 6, and showing binding activity to a spike protein receptor binding domain of SARS-COV-2. ### Claim 20 (depends on 19) The non-natural polypeptide of claim 19, having an amino acid sequence of at least one of SEQ ID NOs: 1, 2, 3, 4, 5, or 6.